Click to Enlarge
A new Alzheimer’s drug called donanemab could be available on the NHS by 2025, the i reports, hailing it as a “breakthrough”. Researchers have found that treatment appears to slow the pace of the disease by a third, but there are some potential side effects – including brain swelling, the paper notes. There is also coverage of the wildfires currently affecting parts of Greece.